Stafford Township

Researchers are evaluating WSD0922-FU in a Phase II, open-label, multicenter study for patients with locally advanced or metastatic non-small cell lung cancer NSCLC whose disease has progressed after first-line treatment with Osimertinib and whose tumors have a C797S mutation in the EGFR gene. This mutation causes resistance to prior treatments, and the study aims to assess safety and effectiveness of this new drug in this specific patient group. WSD0922-FU is an oral drug taken in 21-day cycles, administered twice daily BID at one of two dose levels selected from earlier studies. The drug targets specific EGFR mutations including the resistant C797S mutation. This single-arm study will treat all participants with WSD0922-FU and monitor responses over time. Participants will be closely monitored with assessments every 8 weeks for up to one year to measure tumor response, disease control, progression-free survival, and quality of life using standardized questionnaires. Survival outcomes will be followed for up to 24 months. Safety and side effects will also be recorded throughout the study. The study duration and follow-up are designed to thoroughly evaluate the drugs effects in this advanced NSCLC population.

Researchers are evaluating two digital mindfulness-based interventions to improve mental health and well-being in younger breast cancer survivors who have elevated depressive symptoms. This phase III randomized trial focuses on women diagnosed at or before age 50, who completed primary cancer treatments at least six months earlier. The study aims to compare the effectiveness of live instructor-led sessions via Zoom and a self-paced app-based program, exploring which approach best supports psychological health in this population. Participants will be assigned to one of three groups the live online mindfulness sessions MAPs LO conducted weekly for 6 weeks via Zoom, the MAPs App delivering the same content in shorter sessions over 6 weeks, or a meditation-only control group accessing guided audio meditations. Both English and Spanish speakers can participate in the live online and meditation groups, while the app is only available in English. Tablets and internet hotspots are provided if needed. All groups have access to the UCLA MARC mindfulness meditation app throughout the 6-month follow-up. During the study, participants will attend weekly sessions for the live group or engage with app content at home, with usage tracked to measure intervention dose. Researchers will assess depressive symptoms shortly after the intervention and again up to 6 months later, along with fatigue symptoms. They will also investigate factors influencing intervention effects, such as baseline distress and social determinants, and evaluate the cost-effectiveness of the programs. The total study duration includes a 6-week intervention period plus follow-up assessments out to 6 months.

Researchers are evaluating lung cancer screening uptake among patients aged 50 to 80 who are at risk due to smoking history. The study aims to improve lung screening knowledge, awareness, and uptake by using a Social Determinants of Health SDoH screening tool embedded in the Emergency Departments Electronic Health Record EHR. This pilot Type 1 Hybrid Effectiveness-Implementation Trial will first assess the reach of this approach and then test its preliminary effectiveness compared to enhanced usual care. Participants will be randomly assigned to one of two groups. One group will use LungTalk, an interactive iPad-based educational tool tailored to smoking status and barriers, featuring audio, video, and animations to improve lung screening knowledge and beliefs. The other group will receive a non-tailored lung screening pamphlet via email and follow-up navigation support within 48 hours. Both interventions aim to encourage lung cancer screening through education and patient navigation. During the study, participants will be assessed at 1 week, 1 month, and 6 months after the intervention. Researchers will measure lung cancer screening uptake and participants stage of adoption of lung screening. Additional assessments include health literacy, medical mistrust, perceived stigma and risk, benefits and barriers to screening, self-efficacy, knowledge about lung cancer, and fatalism. The study involves data collection from randomized trial methods and EHR records to evaluate outcomes over time.

This research aims to evaluate whether the use of Tamsulosin can reduce the high rate of postoperative urinary retention POUR in older men undergoing thoracic cancer surgery. POUR is a common issue, especially in older men with enlarged prostates, leading to urinary tract infections, discomfort, and longer hospital stays. This pilot study focuses on men aged 55 and older scheduled for oncological thoracic surgery to see if Tamsulosin can help lower POUR incidence and identify when normal urinary function returns after surgery. Participants will receive a prescription for Tamsulosin at a dose of 0.4 mg daily, starting seven days before their planned surgery and continuing up to the day of surgery. They will take the medication with a meal and record their daily usage in a diary. After surgery, bladder function will be monitored using ultrasound to measure urine volume and residual urine. If spontaneous urination does not occur or excess urine remains, standard bladder management including intermittent catheterization may be applied based on specific guidelines. During the study, researchers will observe and record whether participants can urinate spontaneously within 6 to 8 hours after surgery, the timing and volume of urination within 24 hours, and the amount of residual urine. Those unable to urinate spontaneously may receive catheter interventions. The study will include regular assessments using a BladderScanner and follow participants until urinary function resumes. The total study duration varies depending on surgery and recovery timelines.

Researchers are studying targeted genomic analysis of blood and tissue samples from patients with cancer, focusing on rare cancers with poor prognosis or limited treatment options. This observational research aims to identify genetic changes using genomic sequencing to help understand cancer development and to provide clinicians with mutation data that may guide treatment or referral to relevant studies. The study also collects clinical outcomes and tumor genome data for future analysis and cancer model development. The study involves analyzing previously collected tumor tissue samples using next-generation sequencing to detect mutations. Patients may also provide blood samples for analysis of circulating cell-free DNA and circulating tumor cells. These procedures support the identification of actionable mutations that may have available targeted therapies. The research includes correlative laboratory biomarker analysis. Participants are followed after study completion every 3 months for 2 years, then every 6 months for up to 15 years to monitor clinical outcomes and mutation frequencies. Researchers measure the frequency of specific mutations and the rate of actionable mutations in rare or poor prognosis cancers over this period. This long-term follow-up helps correlate genomic findings with patient outcomes and supports future research developments.

Researchers are studying patients with muscle-invasive urothelial cancer of the bladder, kidney, ureter, or urethra who have had surgery to remove the cancer. The study aims to see if a blood test measuring circulating tumor DNA ctDNA can identify patients at higher risk of cancer returning and who might benefit from additional immunotherapy. This trial evaluates the use of immunotherapy drugs nivolumab and relatlimab to determine if they can improve survival and delay cancer progression after surgery. Participants are divided into two groups based on their ctDNA blood test results. Those with positive ctDNA are randomly assigned to receive either nivolumab alone or nivolumab combined with relatlimab, given intravenously every 28 days for up to 12 cycles. Those with negative ctDNA are randomized to immediate nivolumab treatment or surveillance with regular ctDNA monitoring and nivolumab treatment if ctDNA becomes positive. Throughout the trial, patients undergo tissue and blood sample collection, imaging scans like CT or MRI, and may have cystoscopy. During the study, participants have regular assessments including blood tests, imaging, and quality of life questionnaires. Researchers track ctDNA clearance, disease-free survival, overall survival, and adverse events for up to five years after treatment. Follow-up visits occur at specific weeks up to nearly five years post-treatment to monitor long-term outcomes and safety. The trial also explores the relationship between ctDNA levels and cancer progression along with the cost and value of different treatment approaches.